RxDoctor Payments DataLook up a doctor →

Lyndsay Willmott, MD

Gynecologic Oncology · Phoenix, AZNPI 1043229529

Payments from drug & device makers

$4,000,593in general payments, 2019–2025

Across 742 payments — averaging $5391.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$1.4M
  • Genmab U.S., Inc.$1.1M
  • GSK$600K
  • Genentech, Inc.$321K
  • AstraZeneca$198K
  • Clovis Oncology, Inc.$98K
  • plus $278K from 43 others
$1,599in research payments, 2019–2025

Across 4 payments — averaging $399.81 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • F. Hoffmann-la Roche AG$2K

What the payments were for

  • Consulting fees$97,78622%
  • Speaking & faculty fees$277,27262%
  • Travel & lodging$58,62413%
  • Food & beverage$14,1203%
  • Education$610%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,000,593 in reported general payments places this provider in the 95th percentile of 26 gynecologic oncology providers in Arizona.

See all gynecologic oncology providers in Arizona

Medicare billing

Part B allowed, 2024
$92,872
Medicare patients
180
Services billed
424

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dexamethasone40$790
Estradiol15$769
Ondansetron OdtOndansetron50$720
Prochlorperazine Maleate49$626
Lidocaine-PrilocaineLidocaine/Prilocaine25$276
Venlafaxine Hcl ErVenlafaxine Hcl14$178
Gabapentin15$86

Paid to pharmacies, not to this prescriber.

Other gynecologic oncology in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →